RCKT Rocket Pharmaceuticals, Inc.
Debt Financing ·
Hercules Capital is the lender. Rocket received $35 million at closing, reported no revenue in 2025 or 2024, and held $283.7 million in cash and investments at June 30, 2026.
Rocket Pharmaceuticals received $35 million at closing under a credit facility of up to $150 million with Hercules Capital. The company expects its cash, with that first draw, to fund operations into the third quarter of 2028, and it says more borrowing could extend that into 2029.
Ho and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed.
Rocket received $180.0 million in gross proceeds from a large pharmaceutical company. It says pro forma cash of approximately $322.6 million should fund operations into the second quarter of 2028.
Rocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million.
Rocket Pharmaceuticals priced 13,200,000 shares at $12.50 on December 10, 2024, below the $13.84 last sale price on December 9. Net proceeds are about $154.8 million before the underwriters' option, and the company's own prospectus says the money will last into the second quarter of 2026.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $142.0 million | $171.2 million |
| Net income (loss) | -$223.1 million | -$258.7 million |
| Cash from operations | -$190.0 million | -$209.7 million |
| Cash and equivalents | $77.6 million | $163.6 million |
| Short-term investments | $111.4 million | $208.7 million |
Our latest story on this, dated Aug 10, 2026: "Rocket Pharmaceuticals faces securities class action and derivative suit over Danon trial". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 10, 2024: "Rocket Pharmaceuticals launches $150,000,000 stock offering, prices at $12.50". The story links the filing or release it is based on. Read the story.
Rocket Pharmaceuticals, Inc. trades under the ticker RCKT on NASDAQ.
Rocket Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:9IP1; LS:A2JA9Q; LSX:A2JA9Q.
The SEC Central Index Key (CIK) for Rocket Pharmaceuticals, Inc. is 1281895. Its filings are on SEC EDGAR.
109,774,597 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Rocket Pharmaceuticals, Inc. under United States.
Our directory classifies Rocket Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Rocket Pharmaceuticals, Inc. is US77313F1066.
aibio.space lists Rocket Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Rocket Pharmaceuticals, Inc. reported a net loss of $223.1 million for the fiscal year ended Dec 31, 2025, and used $190.0 million of cash in operations, per its annual report to the SEC.
$142.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$283.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Offered to buy back its own securities. SEC Form SC TO-I. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio